Please assess the completion status of the following clinical trial:

Trial Title: Belatacept Early Steroid Withdrawal Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female patients \> 18 years of age.~2. Patient who is receiving a renal transplant from a living or deceased donor.~3. Female patients of child bearing potential must have a negative urine or serum pregnancy test within the past 48 hours prior to study inclusion.~4. The patient has given written informed consent to participate in the study.~Exclusion Criteria:~1. Patient has previously received an organ transplant other than a kidney.~2. Patient is receiving an human leucocyte antigen (HLA) identical living donor transplant.~3. Patient who is a recipient of a multiple organ transplant.~4. Patient has a most recent cytotoxic panel reactive antibody (PRA) of \>25% or calculated PRA of \> 50% where multiple moderate level HLA antibodies exist and in the opinion of the PI represents substantial HLA sensitization.~5. Patient with a positive T or B cell crossmatch that is primarily due to HLA antibodies.~6. Patient with a donor specific antibody (DSA) as deemed by the local PI to be associated with significant risk of rejection.~7. Patient has received a blood group (ABO) incompatible donor kidney.~8. The donor and/or donor kidney meet any of the following extended criteria for organ donation (ECD):~   * Donor age \>/= 60 years OR~  * Donor age 50-59 years and 1 of the following:~     * Cerebrovascular accident (CVA) + hypertension + serum creatinine (SCr) \> 1.5 mg/dL OR~    * CVA + hypertension OR~    * CVA + SCr \> 1.5 mg/dL OR~    * Hypertension + SCr \> 1.5 mg/dL OR~  * Cold ischemia time (CIT) \> 24 hours, donor age \> 10 years OR~  * Donation after cardiac death (DCD)~9. Recipients will be receiving a dual or en bloc kidney transplant.~10. Donor anticipated cold ischemia is \> 30 hours.~11. Recipient that is seropositive for hepatitis C virus (HCV) with detectable Hepatitis C viral load are excluded. HCV seropositive patients with a negative HCV viral load testing may be included.~12. Recipients who are Hepatitis B core antibody seropositive are eligible if their hepatitis B viral loads are negative. After transplant, their hepatitis B viral loads will be monitored every three months for the first year after transplant. If hepatitis B viral loads become positive, patients will be treated per institutional standard of care.~13. Patients who are Hepatitis B surface antibody seropositive and who receive a kidney from a Hepatitis B core surface antibody positive donor may be included.~14. Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV).~15. Recipient who is seronegative for Epstein Barr virus (EBV).~16. Patient has uncontrolled concomitant infection or any other unstable medical condition that could interfere with the study objectives.~17. Patients with thrombocytopenia (PLT \< 75,000/mm3), and/or leucopoenia (WBC \< 2,000/mm3), or anemia (hemoglobin \< 6 g/dL) prior to study inclusion.~18. Patient is taking or has been taking an investigational drug in the 30 days prior to transplant.~19. Patient who has undergone desensitization therapy within 6 months prior to transplant.~20. Patient has a known hypersensitivity to belatacept, tacrolimus, mycophenolate mofetil, alemtuzumab, rabbit anti-thymocyte globulin, or glucocorticoids.~21. Patient is receiving chronic steroid therapy at the time of transplant.~22. Patients with a history of cancer (other than non-melanoma skin cell cancers cured by local resection) within the last 5 years, unless they have an expected disease free survival of \> 95%.~23. Patient is pregnant, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by positive human Chorionic Gonadotropin (hCG) laboratory test.~24. Women of childbearing potential must use reliable contraception simultaneously, unless they are status post bilateral tubal ligation, bilateral oophorectomy, or hysterectomy.~25. Patient has any form of substance abuse, psychiatric disorder or a condition that, in the opinion of the investigator, may invalidate communication with the investigator.~26. Inability to cooperate or communicate with the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Alemtuzumab + belatacept + mycophenolate mofetil /Enteric coated mycophenolate sodium + early cessation of steroids
- Group B (Type: EXPERIMENTAL): Rabbit antithymocyte globulin + belatacept + mycophenolate mofetil /Enteric coated (EC) mycophenolate sodium + early cessation of steroids
- Group C (Type: ACTIVE_COMPARATOR): Rabbit antithymocyte globulin + tacrolimus + mycophenolate mofetil /Enteric coated (EC) mycophenolate sodium + early cessation of steroids

Based on this trial design, predict the completion outcome and termination type (if applicable).